Last quarter (Q4 2022), Neuren Pharmaceuticals Limited's total revenue was $―, a decrease of ― from the same quarter last year. In Q4, Neuren Pharmaceuticals Limited's net income was $―. See Neuren Pharmaceuticals Limited’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 22	Dec 21	Dec 20	Dec 19	Dec 18
Total Revenue	$ ―	$ 14.55M	$ ―	$ ―	$ ―	$ ―
Cost of Revenue	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Gross Profit	$ ―	$ 14.55M	$ ―	$ ―	$ ―	$ ―
Operating Expense	$ ―	$ 16.16M	$ 11.44M	$ 9.53M	$ 11.57M	$ 8.18M
Operating Income	$ ―	$ -1.61M	$ -11.44M	$ -9.53M	$ -11.57M	$ -8.18M
Net Non Operating Interest Income Expense	$ ―	$ 391.00K	$ 41.00K	$ 147.00K	$ 389.00K	$ 218.00K
Other Income Expense	$ ―	$ 1.39M	$ 3.60M	$ 186.00K	$ 366.00K	$ 11.03M
Pretax Income	$ ―	$ 184.00K	$ -7.79M	$ -9.19M	$ -10.82M	$ 3.07M
Tax Provision	$ ―	$ 0.00	$ 0.00	$ 0.00	$ 0.00	$ 0.00
Earnings From Equity Interest Net Of Tax	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Net Income Common Stockholders	$ ―	$ 184.00K	$ -7.79M	$ -9.19M	$ -10.82M	$ 3.07M
Basic EPS	$ ―	$ <0.01	$ -0.07	$ -0.09	$ -0.11	$ 0.03
Diluted EPS	$ ―	$ <0.01	$ -0.07	$ -0.09	$ -0.11	$ 0.03
Basic Average Shares	$ ―	$ 125.97M	$ 117.77M	$ 107.06M	$ 100.17M	$ 99.04M
Diluted Average Shares	$ ―	$ 125.97M	$ 117.77M	$ 107.06M	$ 100.17M	$ 99.04M
Dividend Per Share	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Total Operating Income As Reported	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Reported Normalized Basic E P S	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Reported Normalized Diluted E P S	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Rent Expense Supplemental	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Total Expenses	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Net Income From Continuing And Discontinued Operation	$ ―	$ 184.00K	$ -7.79M	$ -9.19M	$ -10.82M	$ 3.07M
Normalized Income	$ ―	$ 184.00K	$ -7.79M	$ -9.19M	$ -10.82M	$ 3.07M
Interest Expense	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
EBIT	$ ―	$ -1.61M	$ -11.44M	$ -9.53M	$ -11.57M	$ -8.18M
EBITDA	$ ―	$ -1.60M	$ -11.43M	$ -9.53M	$ -11.57M	$ -8.18M

Currency in USD

Neuren Pharmaceuticals Limited Earnings and Revenue History

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing